Indication

Hepatorenal syndrome

Hepatorenal syndrome is a life-threatening form of functional renal failure that develops as a complication in patients with advanced liver disease, decompensated cirrhosis with ascites, or acute liver failure. Read more about Hepatorenal syndrome

1 drugs 1 manufacturers

Drugs that treat it

Common Hepatorenal syndrome therapies.

Showing 1–1 of 1 drugs

Sort

TERLIVAZ (terlipressin acetate)

ANTIDIURETIC HORMONE·HEPATORENAL SYNDROME

MALLINCKRODT HO

Filter & compare in the drug finder →Opens the drug finder with Hepatorenal syndrome preselected.

News & literature

Coming soon

Related codes

Coming soon

About Hepatorenal syndrome.

The condition primarily impacts the renal and cardiovascular systems in the setting of severe portal hypertension.

Pathophysiologically, portal hypertension induces splanchnic arterial vasodilation, resulting in reduced effective circulating arterial blood volume.

This triggers marked compensatory activation of endogenous vasoconstrictor pathways—including the renin-angiotensin-aldosterone and sympathetic nervous systems—causing profound renal vasoconstriction, severely reduced renal blood flow, and a rapid decline in glomerular filtration rate despite structurally intact kidneys.

nih.gov
Hepatorenal syndrome is a life-threatening form of functional renal failure that develops as a complication in patients with advanced liver disease, decompensated cirrhosis with ascites, or acute liver failure The condition primarily impacts the renal and cardiovascular systems in the setting of severe portal hypertension Pathophysiologically, portal hypertension induces splanchnic arterial vasodilation, resulting in reduced effective circulating arterial blood volume This triggers marked compen...
wikipedia.org
Hepatorenal syndrome is a life-threatening form of functional renal failure that develops as a complication in patients with advanced liver disease, decompensated cirrhosis with ascites, or acute liver failure
nih.gov
Hepatorenal syndrome is a life-threatening form of functional renal failure that develops as a complication in patients with advanced liver disease, decompensated cirrhosis with ascites, or acute liver failure
intechopen.com
The condition primarily impacts the renal and cardiovascular systems in the setting of severe portal hypertension
nih.gov
Pathophysiologically, portal hypertension induces splanchnic arterial vasodilation, resulting in reduced effective circulating arterial blood volume
nih.gov
This triggers marked compensatory activation of endogenous vasoconstrictor pathways—including the renin-angiotensin-aldosterone and sympathetic nervous systems—causing profound renal vasoconstriction, severely reduced renal blood flow, and a rapid decline in glomerular filtration rate despite structurally intact kidneys
armandoh.org
This triggers marked compensatory activation of endogenous vasoconstrictor pathways—including the renin-angiotensin-aldosterone and sympathetic nervous systems—causing profound renal vasoconstriction, severely reduced renal blood flow, and a rapid decline in glomerular filtration rate despite structurally intact kidneys
aasld.org
This triggers marked compensatory activation of endogenous vasoconstrictor pathways—including the renin-angiotensin-aldosterone and sympathetic nervous systems—causing profound renal vasoconstriction, severely reduced renal blood flow, and a rapid decline in glomerular filtration rate despite structurally intact kidneys

Personalize your experience

Follow Hepatorenal syndrome and get updates as they land.

Create a free account

Already a member? Sign in

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it